Nov 20 (Reuters) – A Missouri judge on Friday approved Bayer’s $7.25 billion settlement of lawsuits alleging that its weedkiller Roundup causes cancer, a decision that could ultimately resolve litigation that has weighed on the company for a decade. Bayer is facing approximately 65,000 claims in US state and federal courts from plaintiffs who say […]
U.S.
Missouri judge approves Bayer’s $7.25 billion Roundup settlement
Audio By Carbonatix
Nov 20 (Reuters) – A Missouri judge on Friday approved Bayer’s $7.25 billion settlement of lawsuits alleging that its weedkiller Roundup causes cancer, a decision that could ultimately resolve litigation that has weighed on the company for a decade.
Bayer is facing approximately 65,000 claims in US state and federal courts from plaintiffs who say they developed cancer after using Roundup at home or on the job. The settlement, announced in February, aims to resolve nearly all current and future Roundup claims in the US.
The litigation has weighed on Bayer since its 2018 acquisition of Monsanto, costing the company billions of dollars and driving down its share price. The company previously spent about $10 billion in 2020 to resolve most of the then-existing Roundup lawsuits, but Bayer was unable to gain court approval of a parallel $1.25 billion settlement that would have resolved future Roundup claims.
Bayer has denied the claims and said that decades of studies have shown Roundup’s key ingredient, glyphosate, is safe and does not cause cancer.
The proposed settlement offers payouts ranging from $10,000 to $165,000 to people who were exposed to Roundup and developed non-Hodgkin lymphoma, a form of cancer. The exact award will depend on factors such as the severity of the person’s cancer, how old they were when they were diagnosed, and whether they were exposed to Roundup at home or at work.
When Bayer announced the settlement, it was still awaiting a US Supreme Court ruling on whether it could be sued over its government-approved warning label for Roundup. Bayer ultimately won that case, undercutting a central claim in many of the lawsuits.
Plaintiffs’ attorneys who support the settlement have said the deal ensures that people with cancer will get paid, at a time when litigation is more uncertain than ever after the Supreme Court ruling in Bayer’s favor. Opponents argued that the deal does not offer enough money, and they said the settlement is designed to trap current and future claimants who would prefer to pursue their lawsuits in court.
The deal excludes lawsuits that have been consolidated in an ongoing federal court proceeding. Bayer says about 200 of those cases are still being litigated, and it has argued that the Supreme Court’s ruling gives it strong defenses to those cases.
(Reporting by Dietrich Knauth and Jonathan Stempel, Editing by Alexia Garamfalvi and Matthew Lewis)

